Unknown

Dataset Information

0

The global impact of SARS-CoV-2 in 181 people with cystic fibrosis.

ABSTRACT: With the growing SARS-CoV-2 pandemic, we need to better understand its impact in specific patient groups like those with Cystic Fibrosis (CF). We report on 181 people with CF (32 post-transplant) from 19 countries diagnosed with SARS-CoV-2 prior to 13 June 2020. Infection with SARS-CoV-2 appears to exhibit a similar spectrum of outcomes to that seen in the general population, with 11 people admitted to intensive care (7 post-transplant), and 7 deaths (3 post-transplant). A more severe clinical course may be associated with older age, CF-related diabetes, lower lung function in the year prior to infection, and having received an organ transplant. Whilst outcomes in this large cohort are better than initially feared overall, possibly due to a protective effect of the relatively younger age of the CF population compared to other chronic conditions, SARS-CoV-2 is not a benign disease for all people in this patient group.

SUBMITTER: McClenaghan E 

PROVIDER: S-EPMC7641525 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

The global impact of SARS-CoV-2 in 181 people with cystic fibrosis.

McClenaghan Elliot E   Cosgriff Rebecca R   Brownlee Keith K   Ahern Susannah S   Burgel Pierre-Régis PR   Byrnes Catherine A CA   Colombo Carla C   Corvol Harriet H   Cheng Stephanie Y SY   Daneau Géraldine G   Elbert Alexander A   Faro Albert A   Goss Christopher H CH   Gulmans Vincent V   Gutierrez Hector H   de Monestrol Isabelle I   Jung Andreas A   Justus Lutz Nährlich LN   Kashirskaya Nataliya N   Marshall Bruce C BC   McKone Edward E   Middleton Peter G PG   Mondejar-Lopez Pedro P   Pastor-Vivero M Dolores MD   Padoan Rita R   Rizvi Samar S   Ruseckaite Rasa R   Salvatore Marco M   Stephenson Anne L AL   Filho Luiz Vicente R da Silva LVRDS   Melo Joel J   Zampoli Marco M   Carr Siobhán B SB  

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society 20201104 6

With the growing SARS-CoV-2 pandemic, we need to better understand its impact in specific patient groups like those with Cystic Fibrosis (CF). We report on 181 people with CF (32 post-transplant) from 19 countries diagnosed with SARS-CoV-2 prior to 13 June 2020. Infection with SARS-CoV-2 appears to exhibit a similar spectrum of outcomes to that seen in the general population, with 11 people admitted to intensive care (7 post-transplant), and 7 deaths (3 post-transplant). A more severe clinical c  ...[more]

Similar Datasets

Unknown A multinational report to characterise SARS-CoV-2 infection in people with cystic fibrosis.
| S-EPMC7183287 | biostudies-literature
Unknown SARS-CoV-2 (COVID-19) and cystic fibrosis.
| S-EPMC7518058 | biostudies-literature
Unknown Incidence of SARS-CoV-2 in people with cystic fibrosis in Europe between February and June 2020.
| S-EPMC8053246 | biostudies-literature
Unknown Poor Respiratory Health Following Relapsing SARS-CoV-2 Infection in Children with Cystic Fibrosis.
| S-EPMC8796594 | biostudies-literature
Unknown Physical activity for cystic fibrosis: perceptions of people with cystic fibrosis, parents and healthcare professionals.
| S-EPMC7502697 | biostudies-literature
Clinical Colorectal Cancer Screening in Cystic Fibrosis
| 2726863 | ecrin-mdr-crc
Unknown Resolvin D1 and D2 reduce SARS-CoV-2-induced inflammatory responses in cystic fibrosis macrophages.
| S-EPMC8250053 | biostudies-literature
Unknown A new era for people with cystic fibrosis.
| S-EPMC8346380 | biostudies-literature
Unknown Structures from "Engineering Neutralizing SARS-CoV Antibodies to Bind SARS-CoV-2"
| S-BSST379 | biostudies-other
Unknown Exposure to bile and gastric juice can impact the aerodigestive microbiome in people with cystic fibrosis.
| S-EPMC9247099 | biostudies-literature